FILE PHOTO: A box of material for rapid COVID-19 antigenic tests made by Swiss drugmaker Roche is pictured at the University Hospital (CHUV) during the coronavirus disease (COVID-19) outbreak in Lausanne, Switzerland, November 13, 2020. REUTERS/Denis Balibouse
ZURICH (Reuters) - Roche's Actemra helped the sickest COVID-19 patients in a 303-patient study, the trial's lead investigator said on Thursday, bolstering what has been mixed evidence that the arthritis drug can be repurposed to help in the pandemic.
Actemra, an anti-inflammation drug also called tocilizumab, reached a "key efficacy endpoint" among critically ill patients, compared with patients who did not get immune modulation treatments, according to early REMAP-CAP trial data.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
